IL23R and Crohn disease: In fact, our findings were well correlated with the report about GSE111761 that in patients with Crohn’s disease receiving anti-TNF therapy, there were significant upregulations of mucosal Il-23p19, Il23R and Il17A in non-responders, but not in responders.